by Aline Fieck | Jul 27, 2025 | Featured, News
Toronto, Canada – July 28, 2025 – Qynapse, a technology company using AI to enhance the quantification and predictive capabilities of imaging to improve outcomes for neurological diseases, including Alzheimer’s disease (AD), presented new data at the Alzheimer’s...
by Aline Fieck | May 6, 2025 | Featured, News
PARIS, FRANCE, May 6, 2025 – We are thrilled to share that Qynapse’s collaborative study with Amsterdam UMC has been published in Alzheimer’s Research & Therapy: “Clinical phenotypes of Alzheimer’s disease: investigating atrophy patterns and their pathological...
by Aline Fieck | Apr 5, 2025 | Featured, News
PARIS, FRANCE, April 5, 2025 –Dr. Luca Villa, Senior Clinical Scientist, presented our work focused on using QyScore® and QyPredict® to differentiate patients with progressive supranuclear palsy from patients with Parkinson’s disease. The presentation, titled...
by Aline Fieck | Feb 12, 2025 | Featured, News
PARIS, FRANCE, February 12, 2024 – Qynapse had the pleasure of participating in “Challenges of AI in Healthcare”, an event organized by PariSanté Campus and French Healthcare Association as part of the AI Action Summit in Paris. This gathering brought...
by Aline Fieck | Jan 15, 2025 | Featured, News
PARIS, FRANCE, January 15 28, 2025 – Qynapse congratulates Anavex Life Sciences on the peer-reviewed publication of the ANAVEX®2-73-AD-004 Phase IIb/III clinical trial in The Journal of Prevention of Alzheimer’s Disease. This 48-week randomized, placebo-controlled...
by Administrators Qynapse | May 10, 2024 | Featured, News
PARIS, FRANCE, May 8, 2024 – Our CEO, Olivier Courrèges, will be presenting at the HITLAB Summit in New York City this week! Olivier’s presentation “AI Opening a New Era of Prediction and Monitoring for CNS Diseases.” is scheduled for May 8th at...
